Additionally, the manipulation of FOXO1 can regulate the PD-1 axis in the tumor-infiltrating T cells, which are the primary immune effector cells of the TME, indicating a novel therapeutic strategy for cancer treatment [45]. This evidence concerns the gene FOXO1 and cancer.